Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia / Najlacnejšie knihy
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Kód: 09341330

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Autor KIZAKI MASAHIRO

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for ... celý popis

106.44

Bežne: 111.72 €

Ušetríte 5.29 €


Skladom u dodávateľa
Odosielame za 12 - 14 dní
Pridať medzi želanie

Mohlo by sa vám tiež páčiť

Darčekový poukaz: Radosť zaručená
  1. Darujte poukaz v ľubovoľnej hodnote, a my sa postaráme o zvyšok.
  2. Poukaz sa vzťahuje na všetky produkty v našej ponuke.
  3. Elektronický poukaz si vytlačíte z e-mailu a môžete ho ihneď darovať.
  4. Platnosť poukazu je 12 mesiacov od dátumu vystavenia.

Objednať darčekový poukazViac informácií

Viac informácií o knihe Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Nákupom získate 267 bodov

Anotácia knihy

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owes much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the epidemic defects of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. In spite of associated adverse cardiac events, ponatinib is showing substantial efficacy in imatinib-resistant cases with T315I gene mutation in the ABL kinase domain. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

Parametre knihy

Zaradenie knihy Książki po angielsku Medicine Clinical & internal medicine Diseases & disorders

106.44

Obľúbené z iného súdka



Osobní odběr Bratislava a 2642 dalších

Copyright ©2008-24 najlacnejsie-knihy.sk Wszelkie prawa zastrzeżonePrywatnieCookies


Konto: Logowanie
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Nákupní košík ( prázdný )

Nakupte za 59,99 € a
máte doručení zdarma.

Twoja lokalizacja: